Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

Original reporting
Published Oct 21, 2026, 4:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Integra LifeSciences (IART) stock is falling today — source image
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The earnings beat on a per‑share basis was offset by a revenue miss and operational risk, leading to a sharp price decline.

02

Market read

The earnings release and guidance miss constitute a primary market‑moving event for IART, driving immediate downside risk.

03

What to watch

Potential cost‑saving measures from the flood cleanup and any insurance recoveries are not reflected in the current guidance.

Relevance 7/10Novelty 7/10Timing: intraday today

Background

Integra LifeSciences disclosed Q3 revenue of $411.2 M and adjusted EPS of $0.59, but highlighted a $7 M hit from flood damage and a Q4 revenue range below analyst expectations.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Shares fell 7.3% after Integra LifeSciences reported Q3 results and gave Q4 revenue guidance below estimates, citing flood‑related disruptions.

Expected impact

downward pressure as investors price in weaker revenue outlook and higher borrowing costs

Evidence & confidence

Guidance below consensus and operational risk from flood damage directly triggered the 7% intraday drop.

Market effects

Medical device sector may see heightened scrutiny on supply‑chain resilience after flood disruption.

U.S. healthcare stocks could face modest pullback as investors reassess risk exposure.

Limited to U.S. listed medical‑device peers; no broader macro effect.

Counterpoint

The stock may be oversold; a bounce could occur if the flood impact is contained and guidance is revised upward.

Key entities

  • Integra LifeSciences

    Medical‑device manufacturer reporting Q3 results and Q4 guidance.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.